Updating results

2 results

Sort: Relevance | Date

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2020.

Technology appraisal guidance In consultation

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 18 March 2020.

Technology appraisal guidance In consultation